ASH 2023 | Updates on the Smart Stop trial: the potential for a chemo-free regimen in the frontline for DLBCL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, speaks on the Smart Stop trial (NCT04978584), which is investigating the efficacy of lenalidomide, tafasitamab, rituximab, and acalabrutinib alone or with combination chemotherapy for the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL). Preliminary results reveal that the combination therapy is highly effective and holds potential as an initial chemotherapy-free treatment, as responses were seen after 4 cycles of treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: Astrazeneca Acerta, Kite Gilead, Sobi, ADC Therapeutics
Research Funding: Astrazeneca Acerta, ALX Oncology, Kite Gilead, Sobi, ADC Therapeutics
Consultancy: Roche Genentech, Hutchinson MedoPharma
